Keros Therapeutics halts two dosing arms of cibotercept Phase 2 trial due to pericardial effusion safety concerns; continues ...

Illumina exec Vik Vaz as CEO to advance biological detection tech for drug research. The company uses what it calls ...

Corcept Therapeutics' dazucorilant fails Phase 2 ALS trial after missing primary endpoint, following October's Cushing's ...

Lonza CEO Wolfgang Wienand plans to exit capsules/health ingredients market and restructure into three business units, with ...